Morgan Stanley Sangamo Therapeutics, Inc Transaction History
Morgan Stanley
- $1.49 Trillion
- Q2 2025
A detailed history of Morgan Stanley transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Morgan Stanley holds 572,768 shares of SGMO stock, worth $389,482. This represents 0.0% of its overall portfolio holdings.
Number of Shares
572,768
Previous 745,761
23.2%
Holding current value
$389,482
Previous $492,000
37.2%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding SGMO
# of Institutions
124Shares Held
51.1MCall Options Held
1.12MPut Options Held
789K-
Vanguard Group Inc Valley Forge, PA9.37MShares$6.37 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT8.08MShares$5.5 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny6.84MShares$4.65 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.7MShares$3.2 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.33MShares$1.59 Million0.0% of portfolio
About SANGAMO THERAPEUTICS, INC
- Ticker SGMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 156,552,992
- Market Cap $106M
- Description
- Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...